Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
2020 · The Lancet Oncology · 625 citations
https://doi.org/10.1016/s1470-2045(20)30011-5
C
Chunxia Chen
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
291
Papers
8.4K
Citations
42
h-index
113
i10-index
Chunxia Chen is an academic researcher from Rutgers, The State University of New Jersey. The author has contributed to research in topics: Immune Cell Function and Interaction & Cancer Immunotherapy and Biomarkers & Radiomics and Machine Learning in Medical Imaging. The author has an h-index of 42, co-authored 248 publications.
Papers by this author
worksCamrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
2023 · The Lancet · 590 citations
https://doi.org/10.1016/s0140-6736(23)00961-3
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
2023 · The Lancet · 590 citations
https://doi.org/10.1016/s0140-6736(23)00961-3
The inhibitory effect against collagen-induced arthritis by Schistosoma japonicum infection is infection stage-dependent
2010 · BMC Immunology · 47 citations
https://doi.org/10.1186/1471-2172-11-28
Dramatic Increase of the RNA Editing for Glutamate Receptor Subunits During Terminal Differentiation of Clonal Human Neurons
1997 · Journal of Neurochemistry · 43 citations
https://doi.org/10.1046/j.1471-4159.1997.69010043.x
Foxp3 Processing by Proprotein Convertases and Control of Regulatory T Cell Function
2008 · Journal of Biological Chemistry · 42 citations
https://doi.org/10.1074/jbc.m807322200
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat